Home › Trials › NCT07389473
Clinical trial Recruiting at 1 site Observational Ages 18 to 65

Long-term psychotropic medication effects on eye movements measured with the Gaize VR headset

Official title: An Observational Study to Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

Run by Gaize · NCT07389473 · Data updated 2026-11-12

This project will test whether the Gaize VR headset can detect eye-movement patterns associated with long-term use of prescribed psychotropic medications in adults.

More ADHD trials

Quick facts

Study typeObservational
Ages18 Years to 65 Years
SexAll
Enrollment50 (estimated)
SponsorGaize
Industry-sponsored
Locations1 site (Philadelphia, Pennsylvania)
StatusRecruiting
StartedApril 17, 2024
Main results expectedDecember 2027
Study endsAugust 2028
Registry record updatedFebruary 5, 2026
Trial IDNCT07389473 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18–65 who have been taking prescribed psychotropic medications for more than three months and have normal or corrected vision are the intended participants.

Probably not a fit

People with significant ocular disease, recent eye surgery or dilation, photosensitive epilepsy, prosthetic or missing eyes, or medical conditions/medications that substantially affect cognition or motor function are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational protocol uses the Gaize VR headset to record eye movements while applying Drug Recognition Expert (DRE) oculomotor tests in a controlled virtual environment. Adults aged 18–65 who have used prescribed psychiatric medications for more than three months and who have normal or corrected vision will be enrolled. Key exclusions include recent eye surgery or dilation, photosensitive epilepsy, clinical blindness, prosthetic eye, significant ocular diseases, or other medical conditions/medications that markedly affect cognition or motor function. Measured eye-movement parameters will be compared to established DRE signatures to determine whether the device can reliably identify medication-associated oculomotor changes.

Why it matters

Potential benefit: If successful, this approach could provide an objective, noninvasive way to monitor medication-related eye movement changes and help clinicians detect side effects earlier.

How similar studies have gone: Traditional DRE oculomotor tests have shown predictable eye-movement changes with various substances, but using a VR headset to detect long-term prescribed psychotropic medication effects is a novel and not well-established application.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adults aged between 18 and 65, having given written informed consent to participate in the research trial.
* Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.
* Normal or corrected to normal vision using either glasses or contact lenses, or surgery.

Exclusion Criteria:

* Enrolled in, or participated in another clinical trial within 30 days before the study
* Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days.
* Had your eyes dilated by a medical doctor in the previous 24 hours.
* Photosensitive epilepsy
* Diagnosed with clinical blindness
* Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded.
* Current or past head inject/ traumatic brain injury (TBI)
* Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications.
* History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well.
* Potential participants who are unable to provide consent for the study.

Where it's running

  • Gaize
    Philadelphia, Pennsylvania, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
ADHD 192Depression Disorders 26Mood Disorders 45Anxiety Disorder Generalized 3
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.